What are the advantages of cimepilimab?

Cemiplimab is a fully human monoclonal antibody directed against the immune checkpoint receptor PD-1 on T cells, invented using Regeneron's proprietary VelocImmune technology. By binding to PD-1, cimepilimab has been shown to prevent cancer cells from using the PD-1 pathway to inhibit T cell activation. Cimepilimab is indicated for certain patients with advanced basal cell carcinoma (BCC), advanced cutaneous squamous cell carcinoma (CSCC) and advanced non-small cell lung cancer in the United States and other countries, as well as for patients with advanced cervical cancer in the European Union and other countries.

Cimepilimab's broad clinical program focuses on difficult-to-treat cancers and has demonstrated outstanding anti-tumor activity in the immunotherapy field. As an immune checkpoint inhibitor, it enhances the immune response of T cells by blocking the binding of PD-1 to its ligand, thereby effectively identifying and attacking tumor cells. This mechanism allows it to provide more significant efficacy than traditional treatments in the treatment of advanced or metastatic squamous cell carcinoma, especially in patients for whom chemotherapy is no longer effective.

Clinical trials have shown that the drug's side effects are generally mild and include fatigue, rash and immune-related adverse events. Patients had a greater chance of improving their quality of life when receiving cimepilimab compared with chemotherapy, and it was better tolerated. The drug is usually administered as an intravenous injection, with dosing intervals generally every two weeks. This dosing schedule provides patients with greater convenience and reduces the burden of frequent medical visits. Therefore, it provides a new treatment option for some patients who cannot tolerate traditional treatments.

Cimepilimab is currently being studied as monotherapy and in combination with traditional or novel treatments for other solid tumors and blood cancers. These potential uses are under investigation and their safety and effectiveness have not been evaluated by any regulatory agency.

Reference materials:https://investor.regeneron.com/news-releases/news-release-details/libtayor-cemiplimab-demonstrates-durable-survival-benefit-five/